Visual Impairment Screening using Images from Ophthalmology and Novel pathways for Structural Analysis and Fast Evaluation
VISIONSAFE aims to enhance early detection of preventable eye diseases by extracting and analyzing macro- and microstructural biomarkers from clinical eye images using advanced data science techniques.
Projectdetails
Introduction
Clinical eye images could be explored in an entirely new way to provide early detection of serious eye diseases that currently affect thousands worldwide yet could be preventable. The objective of VISIONSAFE is to extract macro- and microstructure biomarkers from real-world clinical images depicting the retina, lens, and cornea, thereby facilitating early disease detection and personalized management.
Macrostructural vs. Microstructural Biomarkers
While macrostructural biomarkers related to ocular shape are well-established, microstructural biomarkers related to tissue remain largely unexplored. The project's foundation rests on the preliminary work of the PI, which demonstrated the feasibility of deriving disease-related microstructure biomarkers from low-resolution clinical eye images.
Methodology
The approach combines data science, advanced image processing, and rigorous experimental validation to better understand the interplay between macro- and microstructural biomarkers in prevalent sight-threatening eye diseases, including:
- Age-related macular degeneration (AMD)
- Glaucoma
- Cataracts
- Corneal ectasia
This methodology utilizes efficient, cost-effective, and accessible tools.
Ground-breaking Aspects
VISIONSAFE covers several ground-breaking aspects:
- Clinical eye data is already available but underused (can we use data science for vision preservation?).
- The acquisition and combination of macro- and microstructural biomarkers from clinical images have not yet been considered (is this combination a key for the early diagnosis of eye diseases? Are we missing out on essential information from already available data?).
Potential Gains
The project's potential gains are significant. It enhances knowledge on eye disease biomarkers accessible through routine eye exams, shifts the paradigm toward macro- and microstructural biomarker synergy, and represents an important step towards a future where eye diseases are identified and managed earlier. This offers hope and improved quality of life to countless individuals.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.497.873 |
Totale projectbegroting | € 1.497.873 |
Tijdlijn
Startdatum | 1-2-2025 |
Einddatum | 31-1-2030 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- UNIVERSIDAD DE ZARAGOZApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Optical imaging platform for high-throughput longitudinal studies of the eye in disease modelsThe OPTIMEYEZ project aims to enhance a novel multi-contrast optical imaging platform for non-invasive retinal studies, facilitating drug development in neurological diseases while reducing animal use. | ERC Proof of... | € 150.000 | 2023 | Details |
Retinal Mesh OptoelectronicsThe project aims to develop a novel Retinal Mesh Optoelectronics using quantum dots and nanowires for flexible, high-density implants to restore vision in patients with photoreceptor degeneration. | ERC Consolid... | € 2.000.000 | 2022 | Details |
Discovering and Analyzing Visual StructuresThis project aims to assist experts in pattern analysis within unannotated images by developing interpretable visual structures, enhancing discovery in historical documents and Earth imagery. | ERC Starting... | € 1.493.498 | 2023 | Details |
MRI-based ID of the Vasculature across the Heart-Brain AxisDeveloping VascularID, a non-invasive MRI tool for assessing cardiac and cerebral microvasculature, to enhance understanding and treatment of heart-brain axis diseases. | ERC Starting... | € 1.852.430 | 2023 | Details |
Fingerprinting Single Protein Molecules for Biomarker Assisted Precision MedicineSM-ProTrack aims to develop a low-cost, highly sensitive single-molecule sensing technology for detecting AMD biomarkers in small clinical samples, enhancing diagnostic capabilities and commercialization potential. | ERC Proof of... | € 150.000 | 2024 | Details |
Optical imaging platform for high-throughput longitudinal studies of the eye in disease models
The OPTIMEYEZ project aims to enhance a novel multi-contrast optical imaging platform for non-invasive retinal studies, facilitating drug development in neurological diseases while reducing animal use.
Retinal Mesh Optoelectronics
The project aims to develop a novel Retinal Mesh Optoelectronics using quantum dots and nanowires for flexible, high-density implants to restore vision in patients with photoreceptor degeneration.
Discovering and Analyzing Visual Structures
This project aims to assist experts in pattern analysis within unannotated images by developing interpretable visual structures, enhancing discovery in historical documents and Earth imagery.
MRI-based ID of the Vasculature across the Heart-Brain Axis
Developing VascularID, a non-invasive MRI tool for assessing cardiac and cerebral microvasculature, to enhance understanding and treatment of heart-brain axis diseases.
Fingerprinting Single Protein Molecules for Biomarker Assisted Precision Medicine
SM-ProTrack aims to develop a low-cost, highly sensitive single-molecule sensing technology for detecting AMD biomarkers in small clinical samples, enhancing diagnostic capabilities and commercialization potential.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared careI(eye)-Screen aims to develop an AI-based system for early detection and monitoring of age-related macular degeneration, enhancing accessibility and health equity in vision care. | EIC Pathfinder | € 3.454.613 | 2024 | Details |
Automated retinal scans for early detection of diabetic eye diseases through use of artificial intelligenceOivi aims to enhance accessibility to affordable eye care by developing a low-cost, automated retinal imaging device for early detection of diabetic retinopathy, preventing blindness in millions. | EIC Accelerator | € 2.499.999 | 2023 | Details |
ADAPTIVE OPTICAL METASURFACES FOR REAL-TIME, LABEL-FREE AND NON-DESTRUCTIVE 7D DIGITAL PATHOLOGYOPTIPATH aims to revolutionize tissue diagnosis by providing real-time, non-destructive 3D imaging using advanced optical technologies and machine learning to enhance accuracy and reduce variability. | EIC Pathfinder | € 3.276.577 | 2025 | Details |
Haalbaarheid van bevolkingsonderzoek met behulp van kunstmatige intelligentieHet project ontwikkelt een AI-gebaseerde dienst voor vroegtijdige glaucoomdetectie om kosten te verlagen en de impact van blindheid te beperken door bevolkingsonderzoek te verbeteren. | Mkb-innovati... | € 19.472 | 2023 | Details |
NATURAL INTRAOCULAR PHOTOACTIVATION OF COMPOUNDS TO FIGHT RETINOPATHIESThis project aims to revolutionize retinopathy treatment by developing orally bioavailable drugs that target retinal tissue, reducing side effects and improving access to care. | EIC Pathfinder | € 2.988.434 | 2022 | Details |
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
I(eye)-Screen aims to develop an AI-based system for early detection and monitoring of age-related macular degeneration, enhancing accessibility and health equity in vision care.
Automated retinal scans for early detection of diabetic eye diseases through use of artificial intelligence
Oivi aims to enhance accessibility to affordable eye care by developing a low-cost, automated retinal imaging device for early detection of diabetic retinopathy, preventing blindness in millions.
ADAPTIVE OPTICAL METASURFACES FOR REAL-TIME, LABEL-FREE AND NON-DESTRUCTIVE 7D DIGITAL PATHOLOGY
OPTIPATH aims to revolutionize tissue diagnosis by providing real-time, non-destructive 3D imaging using advanced optical technologies and machine learning to enhance accuracy and reduce variability.
Haalbaarheid van bevolkingsonderzoek met behulp van kunstmatige intelligentie
Het project ontwikkelt een AI-gebaseerde dienst voor vroegtijdige glaucoomdetectie om kosten te verlagen en de impact van blindheid te beperken door bevolkingsonderzoek te verbeteren.
NATURAL INTRAOCULAR PHOTOACTIVATION OF COMPOUNDS TO FIGHT RETINOPATHIES
This project aims to revolutionize retinopathy treatment by developing orally bioavailable drugs that target retinal tissue, reducing side effects and improving access to care.